Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Kif15/ULK1 Inhibitor
(Z/E)-GW406108X serves as a selective inhibitor of Kif15, a member of the Kinesin-12 family, with an IC50 of 0.82 µM. This compound is instrumental in studying the dynamics of mitotic processes and cellular transport mechanisms. Additionally, it may have implications in cancer research, specifically in the investigation of tumor cell proliferation and migration. -
IKKε/TBK-1 Inhibitor
MRT67307 dihydrochloride is a potent inhibitor of IKKε and TBK-1, demonstrating IC50 values of 160 nM and 19 nM, respectively. Additionally, this compound inhibits ULK1 and ULK2 with IC50s of 45 nM and 38 nM, respectively. MRT67307 dihydrochloride plays a significant role in blocking autophagy in cellular environments, making it a valuable tool for studies involving inflammation and autophagic processes. -
Autophagy Inhibitor
ATG12-IN-1 is an autophagy inhibitor that effectively disrupts the ATG12-ATG3 protein-protein interaction, exhibiting an IC50 of 9 μM. This compound is valuable in cancer research, allowing for the exploration of autophagy dynamics and its implications in tumor biology. It provides a robust tool for investigating the role of autophagy in cancer progression and therapeutic resistance. -
Autophagy Inhibitor
Autophagy-IN-4 (Compound 34) is a potent autophagy inhibitor, demonstrating an EC50 of 0.5 μM in U2OS cells and an LD50 of 27 μM. This compound effectively interferes with the autophagic process, making it a valuable tool for researchers investigating the role of autophagy in various biological contexts and disease models. Its specificity and efficacy support its application in studies aimed at understanding autophagy-related pathways and potential therapeutic interventions. -
Autophagy Inhibitor
Autophagy-IN-3 is an autophagy inhibitor that enhances metabolic stress within the tumor microenvironment. By inhibiting autophagic processes, it significantly increases the efficacy of cytostatics in combination therapies. This compound is particularly valuable in cancer research, where modulating autophagy can influence tumor growth and treatment response. -
ATG4B Inhibitor
MJO445 is a selective inhibitor of ATG4B, a key regulator in the autophagy pathway. Its inhibition of ATG4B disrupts the autophagic process in glioblastoma cells, thereby enhancing the efficacy of therapeutic strategies against this aggressive cancer. MJO445 is particularly relevant for research focused on cancer biology, autophagy modulation, and the development of novel cancer treatments. -
Autophagy Inhibitor
Autophagy-IN-C1 is a potent autophagy inhibitor that effectively inhibits the autophagic process in hepatocellular carcinoma (HCC) cells. In addition to its role in blocking autophagy, this compound also induces apoptosis, making it a valuable tool for investigating cell death mechanisms and therapeutic strategies in cancer research. Its dual activity provides insights into the interplay between autophagy and apoptosis in tumor biology. -
ULK1/ULK2 Inhibitor
SBP-5147 is a potent inhibitor of ULK1 and ULK2, exhibiting an IC50 of 2 nM for ULK1 and 53 nM for ULK2. This compound effectively inhibits the phosphorylation of Beclin-1 and Vps34, reduces autophagic flux, and downregulates the expression of key autophagy-related proteins ATG13 and ATG101. Additionally, SBP-5147 enhances MHC-I expression, induces caspase-dependent apoptosis, and decreases the viability of non-small cell lung cancer cells. Its mechanism of action makes SBP-5147 a valuable tool for research in non-small cell lung cancer and autophagy modulation. -
Autophagy Inhibitor
Autophagy-IN-7 is an autophagy inhibitor that targets the autophagic process in cells. It is primarily utilized in cancer research to investigate the effects of autophagy modulation on tumor progression and treatment response. This compound serves as a valuable tool for elucidating the role of autophagy in various cellular mechanisms and cancer biology. -
Autophagy Inhibitor
CP 53631 is an autophagy inhibitor that demonstrates anticancer activity by disrupting the autophagic process in cancer cells. This compound can also serve as an internal standard in studies examining selective serotonin reuptake inhibitors (SSRIs) such as Sertraline, making it valuable for research in antidepressant mechanisms and effects. Its dual applications in oncology and neuropharmacology underscore its significance in advancing both fields. -
TbCATL Inhibitor
CAA-0225 is a selective inhibitor of the tissue protease L, specifically targeting TbCATL with an IC50 of 1.9 nM. This compound has demonstrated significant biological activity, including the degradation of autophagosome membrane markers such as LC3-II and GABARAP. Additionally, CAA-0225 improves cardiac function in models of reperfusion injury and exhibits efficacy against Trypanosoma brucei, highlighting its potential applications in cardiovascular research and parasitology studies. -
CXCR4/STAT3 Inhibitor
Minecoside is a potent inhibitor of the CXCR4 receptor and STAT3 signaling pathway. It demonstrates significant anticancer and anti-inflammatory activities by downregulating CXCR4 expression and suppressing STAT3 activation, which leads to the inhibition of CXCL12-induced cellular invasion. Minecoside has been shown to effectively hinder cancer metastasis and enhance apoptosis, making it a valuable tool for research in cancer biology and therapeutic development. -
Cathepsin Inhibitor
LV-320 is a potent uncompetitive inhibitor of cathepsin ATG4B, exhibiting an IC50 of 24.5 μM and a Kd of 16 μM. This compound effectively inhibits the enzymatic activity of ATG4B, thereby obstructing autophagic flux in cellular environments. Due to its stability and low toxicity, LV-320 is suitable for in vivo applications, making it a valuable tool for research on autophagy-related pathways. -
Autophagy Inhibitor/Purinergic Receptors Antagonist
Indophagolin is a potent autophagy inhibitor targeting purinergic receptors, demonstrating an IC50 of 140 nM. It effectively antagonizes the P2X4, P2X1, and P2X3 receptors with IC50 values of 2.71, 2.40, and 3.49 μM, respectively. Additionally, Indophagolin inhibits Gq-protein-coupled P2Y4, P2Y6, and P2Y11 receptors, with IC50s ranging from 3.4 to 15.4 μM. It exhibits strong antagonistic effects on the serotonin receptor 5-HT6 (IC50=1.0 μM) and moderate effects on multiple serotonin receptors, making it a valuable tool for research into autophagy and neurological pathways. -
Autophagy Inhibitor
Autogramin-1 is a potent autophagy inhibitor that effectively suppresses autophagic processes triggered by nutrient deprivation or mTORC1 inhibition. With an IC50 of 0.17 μM against starvation-induced autophagy and 0.44 μM against Rapamycin-induced autophagy, it serves as a valuable tool for researching the role of autophagy in cellular processes and disease models. This compound provides insights into autophagic regulation and its implications in various cancer and neurodegenerative studies. -
Autophagy Inhibitor
NEO214 is an autophagy inhibitor that acts by preventing autophagy-lysosome fusion, effectively blocking autophagic flux. This compound, a covalent conjugate of the PDE4 inhibitor Rolipram and perillyl alcohol, exhibits anti-cancer activity and is capable of penetrating the blood-brain barrier. Its mechanism involves the activation of mTOR and aggregation of the transcription factor EB (TFEB), promoting the death of glioma cells. NEO214 may provide a strategy to combat chemotherapy resistance in glioblastoma. -
Atg4B Inhibitor
Atg4B-IN-2 is a selective inhibitor of Atg4B with a competitive mechanism, exhibiting a Ki value of 3.1 μM. In addition, it displays moderate inhibitory activity against phospholipase A2, with IC50 values of 11 μM and 3.5 μM for Atg4B and PLA2, respectively. This compound effectively enhances the anticancer efficacy of agents targeting castration-resistant prostate cancer through the inhibition of autophagy, making it a valuable tool for cancer research. -
Autophagy Inhibitor
CUR5g is a selective autophagy inhibitor that targets the fusion of autophagosomes and lysosomes. By inhibiting the recruitment of STX17 to autophagosomes through a UVRAG-dependent mechanism, CUR5g effectively disrupts the degradation of autophagic substrates in cancer cells. This compound enhances the anticancer efficacy of Cisplatin in both in vitro and in vivo models, making it a valuable tool for studying autophagy's role in cancer treatment and potential therapeutic synergies. -
IKKε/TBK-1 Inhibitor
MRT67307 hydrochloride is a selective inhibitor of IKKε and TBK-1, exhibiting IC50 values of 160 nM and 19 nM, respectively. Additionally, it inhibits ULK1 and ULK2 with IC50s of 45 nM and 38 nM, respectively. This compound is employed in research to study autophagy regulation and related cellular processes. It is particularly useful in investigations of inflammatory signaling pathways and cancer biology. -
REV-ERB/Autophagy Inhibitor
ARN5187 is a lysosomotropic ligand targeting REV-ERBβ, known for its dual inhibitory effects on REV-ERB-mediated transcriptional regulation and autophagy. This compound exhibits significant lysosomotropic potency and has cytotoxic properties, leading to the induction of apoptosis. ARN5187 serves as a valuable tool for research into the mechanisms of autophagy and the role of REV-ERBβ in cellular processes. -
Autophagy Inhibitor
IITZ-02 is a lysosomotropic autophagy inhibitor that disrupts lysosomal function, leading to impaired autophagosomal degradation and increased autophagosome accumulation. This compound induces apoptosis through a mitochondria-mediated pathway by abolishing mitochondrial membrane potential. IITZ-02 exhibits potent antitumor activity in MDA-MB-231 xenograft mouse models, making it a valuable tool for cancer research applications focusing on the regulation of autophagy. -
CXCR-4 Inhibitor
SSB-2548 is a selective inhibitor of the chemokine receptor CXCR-4. It has demonstrated significant efficacy in inhibiting the proliferation and migration of acute myeloid leukemia cells, while also promoting apoptosis. Its favorable gastrointestinal absorption profile makes SSB-2548 a valuable tool for investigating the underlying mechanisms of leukemia and exploring potential therapeutic interventions. -
Autophagy Inhibitor
Erythrabyssin II is a potent late-stage autophagy inhibitor that selectively inhibits the fusion of autophagosomes and lysosomes. This compound promotes the accumulation of autophagic substrates without disrupting lysosomal pH or enzyme activity. Erythrabyssin II has demonstrated efficacy in suppressing ovarian cancer organoid growth and inducing apoptosis, making it a valuable tool for research in ovarian cancer studies. -
Autophagy Inhibitor
EAD1 TFA is an autophagy inhibitor that plays a critical role in the regulation of plant growth and development, particularly in maize. This compound is preferentially expressed in the xylem of immature corn ears, where it facilitates the transport of malic acid. Its function is essential for proper ear length and kernel development, with alterations in EAD1 TFA expression correlating with changes in malic acid content. EAD1 TFA represents a valuable tool for researchers investigating the genetic basis of crop yield improvement. -
Autophagy Inhibitor/Ionic Compound
Ammonium chloride is an ionic compound known for its role as an autophagy inhibitor. By inducing intracellular alkalization, it can disrupt lysosomal function and alter enzymatic activity, leading to metabolic acidosis. This compound is widely utilized in research applications focused on autophagy modulation and lysosomal pathway studies. -
Autophagy Inhibitor; p62 ZZ Domain Inhibitor
XRK3F2 is a selective inhibitor of the p62 (sequestosome-1) ZZ domain, demonstrating potent inhibition of autophagy processes. This compound effectively blocks TNFα-induced signaling in bone marrow stromal cells and promotes apoptosis in multiple myeloma cells. XRK3F2 is valuable for research applications targeting multiple myeloma bone disease and acute myeloid leukemia, providing insights into cell survival mechanisms and autophagic regulation in hematological malignancies. -
Cytokinin Nucleoside/Autophagy Inhibitor
N6-Isopentenyladenosine, a cytokinin nucleoside, acts primarily as an autophagy inhibitor. This compound, derived from the mevalonate pathway, has demonstrated notable anti-melanoma activity. Additionally, it plays a critical role in RNA modification, enhancing the efficiency and accuracy of translation in certain tRNAs and regulating plant growth and differentiation. Research applications include investigations into autophagy-related mechanisms and the development of therapeutic strategies for melanoma. -
ATG7 Inhibitor
ATG7-IN-2 is a potent inhibitor of ATG7, demonstrating an IC50 of 0.089 μM. This compound effectively inhibits the autophagy marker LC3B, making it a valuable tool for studies involving autophagy modulation. Researchers can utilize ATG7-IN-2 to investigate the role of autophagy in various biological processes and disease states. -
Autophagy Inhibitor
DC-LC3in-D5 functions as an autophagy inhibitor by inhibiting the lipidation of LC3B. It effectively binds to LC3B and disrupts the interaction with LBP2, exhibiting an IC50 value of 200 nM. This compound is valuable in research focused on the modulation of autophagy, contributing to investigations of anti-HCV therapies and potential cancer treatments through autophagy inhibition. -
Autophagy Inhibitor
ATG7-IN-1 is a selective inhibitor of the autophagy-related protein ATG7, exhibiting an IC50 of 62 nM. This compound interferes with autophagy processes by disrupting the function of ATG7, making it a valuable tool for research in autophagy regulation. It is particularly useful for studies investigating the role of autophagy in various diseases, including cancer and neurodegenerative disorders. -
Autophagy Inhibitor
Autogramin-2 is a potent autophagy inhibitor that effectively blocks autophagy triggered by nutrient deprivation, demonstrating an IC50 of 0.27 μM, as well as autophagy induced by mTORC1 inhibition with Rapamycin, with an IC50 of 0.14 μM. This compound is valuable for studying the role of autophagy in cellular processes and various diseases, including cancer and neurodegeneration. Its ability to modulate autophagic pathways makes it an essential tool for researchers investigating autophagy's impact on cell survival and metabolism. -
Kif15/ULK1 Inhibitor
GW406108X is a selective inhibitor of Kif15 (Kinesin-12) and exhibits a significant inhibition of ULK1 kinase activity with a pIC50 of 6.37 (427 nM). This compound demonstrates potent autophagy inhibition, effectively blocking autophagic flux without impacting upstream signaling pathways such as mTORC1 and AMPK. GW406108X serves as a valuable tool in research focusing on autophagy regulation and related cellular processes. -
ATG7 Inhibitor
ATG7-IN-3 is a highly effective inhibitor of ATG7, exhibiting an IC50 of 0.048 μM. This compound disrupts autophagy by preventing the formation of LC3B puncta, a critical process in the autophagic pathway. Research applications include investigations into glioma and colon cancer, making it a valuable tool for studying the role of autophagy in cancer biology. -
mTOR Inhibitor/Autophagy Inducer
mTOR inhibitor-8 is a potent inhibitor of the mechanistic target of rapamycin (mTOR), functioning through the interaction with FKBP12. This compound effectively suppresses mTOR activity and induces autophagy in A549 human lung cancer cells. It is a valuable tool for studying mTOR signaling pathways and the role of autophagy in cancer research. -
LRRK2 Inhibitor
LRRK2-IN-17 is a potent inhibitor of Leucine-rich repeat kinase 2 (LRRK2), with IC50 values of 3.5 nM and 3.3 nM for wild-type and G2019S mutant variants, respectively. Additionally, it exhibits inhibitory activity against RET kinase with an IC50 of 59 nM. This compound is relevant for research applications related to cancer and Parkinson's disease, making it a valuable tool for investigating the role of LRRK2 in these conditions. -
Autophagy Inhibitor
Leonurine hydrochloride is an alkaloid derived from Leonurus artemisia, acting primarily as an autophagy inhibitor. This compound exhibits notable anti-oxidative and anti-inflammatory properties, making it a valuable tool for research into cellular stress responses and inflammatory processes. It is particularly useful for studying the implications of autophagy modulation in various biological contexts, including neurodegenerative diseases and cancer. -
HIF Inhibitor
Arylsulfonamide 64B is a potent inhibitor of hypoxia-inducible factor (HIF). This compound effectively suppresses hypoxia/HIF-mediated expression of key oncogenes such as c-Met and CXCR4, thereby demonstrating significant anti-tumor activity. Arylsulfonamide 64B is particularly relevant for research focused on uveal melanoma, as it has been shown to reduce primary tumor growth and metastasis in mouse models. -
PPT1 Inhibitor
Ezurpimtrostat (hydrochloride) is a potent and selective PPT1 inhibitor with multiple biological activities. It disrupts lysosomal function, modulates autophagy, and induces apoptosis, making it a valuable tool in cancer research and immunology. This compound has demonstrated efficacy in reducing inflammatory markers such as IFN-α and CRP, as well as in lowering viral loads of SARS-CoV-2. Ezurpimtrostat is suitable for investigating conditions such as systemic lupus erythematosus, hepatocellular carcinoma, fibrosis, and other related disorders. -
CCR5/CXCR4 Chemotaxis Inhibitor
Catenarin, an anthraquinone compound, serves as an inhibitor of CCR5 and CXCR4-mediated chemotaxis. It effectively reduces the phosphorylation of mitogen-activated protein kinases (p38 and JNK) and their upstream kinases (MKK6 and MKK7), as well as calcium mobilization. Catenarin demonstrates anti-inflammatory properties and inhibits leukocyte migration, contributing to its potential in diabetes research. Additionally, it exhibits significant antibacterial activity against Gram-positive bacteria and has been shown to prevent type 1 diabetes in nonobese diabetic mice. -
CXCR5 Inhibitor
YU241279 is a selective inhibitor of CXCR5, targeting the CXCL13-mediated signaling pathways. It effectively inhibits Gαq-dependent calcium influx and Gαi2-dependent cAMP reduction in CXCR5-expressing cells, leading to reduced proliferation of lymphoma cells. In preclinical studies, YU241279 demonstrated a significant reduction in tumor burden within the peripheral blood and bone marrow of mice with lymphoma. This compound is suitable for research into angioimmunoblastic T-cell lymphoma and Burkitt B-cell lymphoma.
